ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
20 announcements
Anuh Pharma disclosed a Rs. 9,93,206 tax demand under Section 156, Income Tax Act, for AY 2018-19. The company plans to appeal before the CIT.
Anuh Pharma reported strong Q1 FY27 results with 4% YoY revenue growth and 38% PAT growth, driven by a shift to high-value regulated markets.
Anuh Pharma announced the re-appointment of directors Arun Lalchand Todarwal and Bipin N. Shah, and the appointment of Ankit Kishor Chande as Cost Auditor.
Anuh Pharma Ltd held its 66th Annual General Meeting on August 12, 2026. The meeting covered the adoption of financial statements, dividend declaration, and director appointments.
Anuh Pharma Ltd. promoters withdrew their application for reclassification from 'Promoter Group' to 'Public' category. They will continue to remain part of the Promoter Group.
Anuh Pharma Ltd reported revenue from operations of ₹193.8 Cr (+3.9% YoY) and net profit of ₹11.4 Cr (+37.3% YoY) for Q1 FY27.
Anuh Pharma Ltd has scheduled a board meeting for August 7, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.
Anuh Pharma Ltd notified the exchange about dispatching physical letters to shareholders regarding the 66th Annual General Meeting and the availability of the FY 2025-26 Annual Report.
Anuh Pharma Ltd has submitted its 66th Annual Report for the financial year 2025-26. The report is now available for shareholders on the company's official website.
Anuh Pharma Ltd. has issued the notice for its 66th Annual General Meeting, scheduled for August 12, 2026, to conduct routine and special business.
Anuh Pharma Ltd submitted its Annual Secretarial Compliance Report for the financial year 2025-2026. The report confirms overall regulatory adherence with no new non-compliances observed.
Anuh Pharma reported FY26 revenue growth of 15.66% YoY to ₹776 Cr, driven by strong volumes in regulated markets and successful USFDA/EU GMP inspections.
Anuh Pharma recommended a final dividend of Rs. 1.50 per equity share for FY2026. Payment is scheduled by September 10, following shareholder approval.
Anuh Pharma Ltd reported full-year audited financial results for the period ending March 31, 2026. The company also declared a final dividend of ₹1.50 per share.
Anuh Pharma Ltd reported revenue from operations of ₹202.1 Cr (+2.0% YoY) and net profit of ₹11.7 Cr (-6.4% YoY) for Q4 FY26.
Anuh Pharma reported a full-year net profit of ₹41.05 Crore. The board recommended a ₹1.50 per share dividend and re-appointed directors Bipin Shah and Arun Todarwal.
Anuh Pharma received requests from nine promoter group members seeking reclassification to the public category. The outgoing group holds a collective 0.95% stake in the company.
Anuh Pharma Ltd received WHO Prequalification approval for its anti-malarial API, Amodiaquine Hydrochloride USP. This approval allows the company to supply international markets, including WHO-procured and donor-funded programmes, consolidating its position as a preferred global supplier.
Anuh Pharma Ltd has confirmed it does not qualify as a 'Large Corporate' for FY 2026-27 as per SEBI criteria. While its equity is listed, it reports zero outstanding long-term borrowings and does not meet the required credit rating thresholds.
Anuh Pharma Ltd submitted its compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026. The Registrar and Share Transfer Agent confirmed that no dematerialization requests for equity shares were received during the period.